FY2025 EPS Estimates for Biogen Reduced by Leerink Partnrs

Biogen Inc. (NASDAQ:BIIB) – Stock analysts at Leerink Partnrs cut their FY2025 earnings estimates for shares of Biogen in a report released on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now forecasts that the biotechnology company will post earnings of $16.50 per share for the year, down from their previous forecast of $17.20. The consensus estimate for Biogen’s current full-year earnings is $16.41 per share. Leerink Partnrs also issued estimates for Biogen’s FY2026 earnings at $16.65 EPS.

Biogen (NASDAQ:BIIB) last announced its earnings results on Wednesday, October 30th. The biotechnology company reported $4.08 EPS for the quarter, topping the consensus estimate of $3.77 by $0.31. The business had revenue of $2.47 billion during the quarter, compared to the consensus estimate of $2.43 billion. Biogen had a net margin of 16.81% and a return on equity of 14.98%. Biogen’s revenue was down 2.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $4.36 EPS.

A number of other analysts also recently issued reports on BIIB. Citigroup cut their price objective on shares of Biogen from $190.00 to $160.00 and set a “neutral” rating for the company in a report on Tuesday. Mizuho cut their price objective on shares of Biogen from $251.00 to $207.00 and set an “outperform” rating for the company in a report on Thursday, November 21st. Raymond James reissued a “market perform” rating on shares of Biogen in a report on Thursday, October 10th. Wolfe Research initiated coverage on shares of Biogen in a report on Friday, November 15th. They issued a “peer perform” rating for the company. Finally, Wells Fargo & Company cut their price target on shares of Biogen from $190.00 to $165.00 and set an “equal weight” rating for the company in a report on Friday, January 10th. Sixteen investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $228.80.

Biogen Stock Performance

Shares of BIIB stock opened at $146.23 on Thursday. The company has a market capitalization of $21.31 billion, a price-to-earnings ratio of 13.21, a PEG ratio of 1.64 and a beta of -0.07. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.80 and a current ratio of 1.26. The company has a 50-day simple moving average of $151.32 and a 200 day simple moving average of $179.80. Biogen has a 52 week low of $139.71 and a 52 week high of $251.99.

Institutional Investors Weigh In On Biogen

Several institutional investors have recently made changes to their positions in the stock. Grandfield & Dodd LLC lifted its position in shares of Biogen by 5.2% during the third quarter. Grandfield & Dodd LLC now owns 1,261 shares of the biotechnology company’s stock worth $244,000 after acquiring an additional 62 shares in the last quarter. Quintet Private Bank Europe S.A. increased its holdings in shares of Biogen by 9.7% in the third quarter. Quintet Private Bank Europe S.A. now owns 710 shares of the biotechnology company’s stock worth $138,000 after purchasing an additional 63 shares during the period. Quent Capital LLC increased its holdings in shares of Biogen by 31.9% in the fourth quarter. Quent Capital LLC now owns 298 shares of the biotechnology company’s stock worth $46,000 after purchasing an additional 72 shares during the period. TD Private Client Wealth LLC increased its holdings in shares of Biogen by 25.0% in the third quarter. TD Private Client Wealth LLC now owns 385 shares of the biotechnology company’s stock worth $75,000 after purchasing an additional 77 shares during the period. Finally, Principal Securities Inc. increased its holdings in shares of Biogen by 30.1% in the fourth quarter. Principal Securities Inc. now owns 337 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 78 shares during the period. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.